BRAF 转移性黑色素瘤之旅：患者和肿瘤医生的视角。
BRAF Metastatic Melanoma Journey: A Perspective from a Patient and his Oncologist.
机构信息
, Bremen, Germany.
Clinic of Dermatology, Elbe Klinikum Buxtehude, Am Krankenhaus 1, 21614, Buxtehude, Germany.
出版信息
Adv Ther. 2024 Jul;41(7):2576-2585. doi: 10.1007/s12325-024-02883-0. Epub 2024 May 28.
BACKGROUND
This article is co-authored by a patient with BRAF metastatic melanoma and his treating oncologist.
CASE DESCRIPTION
The patient describes how he coped with his diagnosis and treatment. He details the pathway of his melanoma treatment, which has spanned over 10 years, including surgical interventions, medical treatment, and participation in clinical trials. He relates his experience of living with the disease-and the adverse effects of treatment-in the long term. The clinical perspective of his treating oncologist reviews the diagnostic process and explains how the therapeutic options were selected for and with the patient. The oncologist also addresses the integration of the patient into clinical trials involving programmed death-1 (PD-1) inhibitors and BRAF/MEK inhibitors. Challenges related to the adverse effects that occurred and the personalised treatment of the patient are also discussed. Finally, the article evaluates current advances in treatment and future therapeutic approaches.
CONCLUSIONS
This case highlights the challenges of identifying which therapeutic options are most appropriate for individual patients with BRAF metastatic melanoma.
背景
本文由一位 BRAF 转移性黑色素瘤患者及其治疗肿瘤学家合著。
病例描述
患者描述了他如何应对诊断和治疗。他详细介绍了他的黑色素瘤治疗途径，该途径已持续了 10 多年，包括手术干预、药物治疗和参与临床试验。他讲述了自己长期患有这种疾病以及治疗副作用的经历。治疗肿瘤学家从临床角度回顾了诊断过程，并解释了如何为患者选择和制定治疗方案。肿瘤学家还介绍了将患者纳入涉及程序性死亡受体-1（PD-1）抑制剂和 BRAF/MEK 抑制剂的临床试验的情况。还讨论了与不良反应和患者个体化治疗相关的挑战。最后，文章评估了当前治疗进展和未来治疗方法。
结论
本病例强调了确定哪些治疗方案最适合 BRAF 转移性黑色素瘤患者的个体患者的挑战。
Zotero 插件